Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) has been assigned an average rating of “Moderate Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $11.00.

Separately, Weiss Ratings upgraded shares of Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th.

Institutional Investors Weigh In On Evaxion A/S

A number of hedge funds have recently bought and sold shares of EVAX. Rathbones Group PLC acquired a new position in Evaxion A/S in the first quarter worth $170,000. Renaissance Technologies LLC acquired a new stake in shares of Evaxion A/S during the 1st quarter valued at $146,000. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Evaxion A/S in the 1st quarter valued at approximately $112,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion A/S Trading Down 1.8%

Shares of EVAX stock opened at $3.21 on Tuesday. The business’s fifty day moving average price is $3.08 and its 200 day moving average price is $3.54. Evaxion A/S has a 1-year low of $2.77 and a 1-year high of $12.15. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.06 and a quick ratio of 5.06. The firm has a market capitalization of $26.77 million, a PE ratio of -2.65 and a beta of 0.26.

Evaxion A/S Company Profile

Evaxion A/S is a Denmark-based biotechnology company that develops immunotherapies and vaccines using artificial intelligence. Its proprietary AI-Immunology platform is designed to analyze biological data, identify disease targets and support the development of treatments tailored to individual patients or specific pathogens.

The company’s research has focused primarily on personalized cancer vaccines and vaccines for infectious diseases. Its pipeline has included EVX-01, an individualized cancer immunotherapy candidate intended to stimulate a patient’s immune system to recognize and attack tumor-specific targets, as well as additional programs directed at cancer and infectious diseases.

Evaxion was founded in Denmark and conducts its research and development activities from the country, serving the international biotechnology and pharmaceutical markets.